Endowhine

Well Goodness IHRT Readers,
So much coming out of Endogyn these days............So much to blog about...like we've got years of material,right from the horses mouths.Dr Kruschinski and the Endogyn Dancers!
Don't you worry dear readers, we are all over it.Look for more shocking revelations regardingDr. Kruschinski,Endogyn,Argentina,Cayman Islands,Letters from Dr Reich,Gang bang away people who ask real questions,( this is great as if it were me I head for the hills)
Go to Italy
Go to the Caymans
Fact is Dr "Gary Cooper" knows time may be short for Endogyn
The long arm of American Law is on it's way. No letter will stop it this time.
( Why does the letter not state something like, " it was so nice to see you in Argentina"?or even "Dear Dr. Kruschinski"? Why is there an irregular spaced gap in the middle of the post?Just so many thing smell like dirty diapers....)One thing is true. No Dr. ever asked us to do what we do, which is to ask tough questions.
Challenge erroneous information.Defend those who are so ill, vulnerable and desperate for hope...Keeping Adhesion Sufferers from false hope and further harm from those willing toPROFIT FROM PAIN
Check out IHRT next week!
Oh ya,Karen's New Screaming, Raving Loony Blog,( Did you ever see the South Park parody of Russell Crow? dum de dum de Fightin round the world)You keep that name as someday I think it will come in handy when everyone involved in the Endogate scandal realizes they have been victims of crime.Then you will really need a "Dr. Kruschinski Support Group
"Helen Blogging????Yes Virginia there is a Santa ClausYes Helen, the FDA and the United states governmentdo recognize Adhesions and Adhesion Related Disorder. ( Thank to the tireless efforts of real ARD advocates)How do you think seprafilm and intergel got approved for use?
How bout this:[PDF] Congressional Justification 2006
File Format: PDF/Adobe Acrobat - View as HTMLAdhesion related disorder – This little known condition commonly leads to ... Adhesion related disorder is not a single disease, but rather describes a type ...www.niddk.nih.gov/federal/pdf/NIDDK_fy06_CJ.PDF - Similar pagesor this just to make yer face a blushing red... Pregabalin for Abdominal Pain From AdhesionsThis study is currently recruiting patients.Verified by Henry Ford Health System December 2005Sponsors and Collaborators:Henry Ford Health SystemPfizerInformation provided by:Henry Ford Health SystemClinicalTrials.govIdentifier:NCT00310765PurposeThe purpose of this study is to evaluate if pregabalin demonstrates significant reduction in abdominal pain from adhesions.The study will be prospective, double-blinded and randomized. The study will run for 12 weeks. During the first 7 weeks there will be 2 groups in the study with subjects receiving a placebo or the study drug. During the last 4 weeks of the study, all subjects will be offered the study medication, pregabalin.
ConditionInterventionPhaseChronic Abdominal Pain Secondary to Surgical AdhesionsDrug: PregabalinPhase IVMedlinePlus consumer health informationStudy Type: InterventionalStudy Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy StudyOfficial Title: Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled TrialFurther study details as provided by Henry Ford Health System:Expected Total Enrollment: 100Study start: March 2006EligibilityAges Eligible for Study: 18 Years and above, Genders Eligible for Study: BothCriteriaInclusion Criteria:must have history of prior surgery and documented adhesions during laparoscopy or open laparotomy within 5 yearsmust have undergone an evaluation to exclude other causes of abdominal painabdominal pain must be present for greater than three months durationExclusion Criteria:patients that are pregnant or breast feedingprior treatment with gabapentin, pregabalin or demonstrated sensitivity to these drugspatients who are immunocompromisedpatients with significant hepatic or renal insufficiency, or any significant hematologic disorderhistory of illicit alcohol or drug abuse within one yeardocumented serious or unstable medical or psychological conditionmalignancy within the past 5 years other than in situ squamous cell carcinoma of the skinLocation and Contact InformationPlease refer to this study by ClinicalTrials.gov identifier NCT00310765Helen Gikas, RN, BSN 248-661-7928 mailto:hgikas1@hfhs.org?subject=NCT00310765,Michigan Henry Ford Health System, West Bloomfield, Michigan, 48322, United States; RecruitingHelen Gikas, RN, BSN 248-661-7928 mailto:hgikas1@hfhs.org?subject=NCT00310765, Ann L Silverman, MD, Principal InvestigatorStudy chairs or principal investigatorsAnn L Silverman, MD, Principal Investigator, Henry Ford Health SystemMore InformationStudy ID Numbers: 3727Last Updated: April 3, 2006Record first received: March 31, 2006
ClinicalTrials.govIdentifier: NCT00310765Health Authority: United States: Institutional Review BoardClinicalTrials.gov processed this record on 2006-04-07
http://www.clinicaltrials.gov/ct/show/NCT00310765;jsessionid=80DA8829BAC946C265C8AE64FA76556C?order=4